News for bluebird bio, Inc. (BLUE)

Published at

Apr 16, 2025 4:00 PM

by gurufocus.com

positive

positive

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

\nbluebird bio, Inc. (NASDAQ: BLUE) (â\u0080\u009cbluebirdâ\u0080\u009d or â\u0080\u009cthe Companyâ\u0080\u009d) today announced that after three weeks of engagement, including a timeline extension, A

BLUE.MX BLUE 0HOH.L

Read more →
Published at

Apr 16, 2025 3:56 PM

by gurufocus.com

positive

positive

bluebird bio (BLUE) Board Endorses Deal Amid Ayrmid's Uncertainty

Investment Highlights:\n bluebird bio (BLUE) is backing an acquisition deal with Carlyle and SK Capital, with a decision deadline set for May 2025. Wall St

BLUE.MX BLUE 0HOH.L

Read more →
Published at

Apr 16, 2025 3:31 PM

by gurufocus.com

positive

positive

Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquisition Deal | BLUE Stock News

Bluebird Bio (BLUE) has announced the continuation of its acquisition strategy with Carlyle and SK Capital, reaffirming its recommendation for shareholders to s

BLUE.MX BLUE 0HOH.L

Read more →
Published at

Mar 28, 2025 11:55 PM

by gurufocus.com

positive

positive

Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premium Offer

Bluebird Bio, Inc. (BLUE) has announced receipt of an unsolicited acquisition offer from Ayrmid Ltd. proposing $4.50 per share in cash plus a one-time contingen

BLUE.MX BLUE 0HOH.L

Read more →
Published at

Mar 28, 2025 11:55 PM

by gurufocus.com

positive

positive

Bluebird Bio (BLUE) Receives Higher Buyout Bid from Ayrmid

Bluebird bio (BLUE) has been presented with an unsolicited acquisition proposal from Ayrmid, offering $4.50 per share in cash plus a contingent value right of $

BLUE.MX BLUE 0HOH.L

Read more →
Published at

Mar 27, 2025 11:25 PM

by zacks.com

positive

positive

Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of -259.70% and 52.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

BLUE

Read more →
Published at

Mar 18, 2025 11:39 AM

by seekingalpha.com

negative

negative

Carlyle's bluebird Deep Discount Buyout (NASDAQ:BLUE)

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by 2027. See why BLUE stock is a Hold.

BLUE

Read more →
Published at

Mar 17, 2025 10:00 PM

by gurufocus.com

positive

positive

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE

PR NewswireNEW YORK, March 17, 2025 NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio,

BLUE.MX BLUE 0HOH.L

Read more →
Published at

Mar 11, 2025 8:00 AM

by gurufocus.com

mixed

mixed

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders

PR NewswireNEW YORK, March 11, 2025 NEW YORK, March 11, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following

WBA JAZZN.MX JAZZ CMRX BLUE.MX BLUE 0HOH.L

Read more →
Published at

Mar 7, 2025 5:00 PM

by gurufocus.com

mixed

mixed

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WBA, IVAC, BLUE on Behalf of Shareholders

PR NewswireNEW YORK, March 7, 2025 NEW YORK, March 7, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

STX IVAC BLUE.MX BLUE 0HOH.L WBA

Read more →
Published at

Mar 3, 2025 8:00 PM

by gurufocus.com

neutral

neutral

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, HUSA, BLUE on Behalf of Shareholders

PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

HUSA BRDG BLUE.MX BLUE 0HOH.L 0A7K.L

Read more →
Published at

Mar 3, 2025 8:00 PM

by gurufocus.com

positive

positive

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE

PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, in

BLUE.MX BLUE 0HOH.L

Read more →
Published at

Feb 25, 2025 6:00 AM

by gurufocus.com

mixed

mixed

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, BLUE on Behalf of Shareholders

PR NewswireNEW YORK, Feb. 24, 2025 NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

AVTE BRDG BLUE.MX BLUE 0HOH.L

Read more →
Published at

Feb 24, 2025 5:55 PM

by seekingalpha.com

positive

positive

bluebird bio stock slides for second day on buyout news (BLUE:NASDAQ)

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

BLUE

Read more →
Published at

Feb 21, 2025 8:17 PM

by benzinga.com

positive

positive

Dow Tumbles Over 700 Points; US Services PMI Falls In February - bluebird bio (NASDAQ:BLUE), Aspire Biopharma Hldgs (NASDAQ:ASBP)

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 700 points on Friday. The Dow traded down 1.63% to 43,457.49 whi...

UPC BLUE.MX BLUE 0HOH.L

Read more →
Published at

Feb 21, 2025 2:53 PM

by benzinga.com

neutral

neutral

What's Going On With Gene Therapy Company Bluebird Bio Stock Today? - bluebird bio (NASDAQ:BLUE)

bluebird bio agrees to be acquired by Carlyle Group and SK Capital, offering stockholders up to $9.84 per share in a strategic buyout.

BLUE.MX BLUE

Read more →
Published at

Dec 29, 2024 12:07 PM

by insidermonkey.com

positive

positive

bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where bluebird bio, Inc.

BLUE.MX BLUE 0HOH.L

Read more →
Published at

Dec 29, 2024 12:40 AM

by insidermonkey.com

positive

positive

10 Best Gene Therapy Stocks to Buy Right Now

Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.

VYGR.MX VYGR MGTX BLUE.MX BLUE 0HOH.L

Read more →
Published at

Dec 22, 2024 6:25 PM

by finance.yahoo.com

mixed

mixed

This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?

Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This new coverage could also make it easier once CRISPR Therapeutics earns approval for other gene-editing medicines.

NVDA CRSP BLUE

Read more →
Published at

Dec 17, 2024 11:29 AM

by finance.yahoo.com

mixed

mixed

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?

The Food and Drug Administration (FDA) approved CRISPR Therapeutics' (NASDAQ: CRSP) first treatment last December, and its successful launch could push the stock much higher. Investment bank analysts also expect Iovance Biotherapeutics (NASDAQ: IOVA) to soar in 2025. Before chasing exciting price targets, though, it's important to remember that analysts who set lofty expectations can quietly adjust them downward if things don't work out.

NFLX IOVA CRSP AAPL NVDA.MI NVDA BLUE

Read more →